EGFR and neoplasm: To our knowledge, LHRH agonists should drop EGFR receptor numbers by different pathways; one would be preventing EGFR-mediated tumor growth through a PKC pathway.[34] However, we have to consider that the immunoassay used in this study assesses the total number of receptors and the results obtained by us could mask or not evidence the real number of active or functioning receptors.